Work

SPYK04, a novel RAF-MEK molecular glue: Dose escalation (DE) in first-in-human study for MAPK pathway-altered solid tumors.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.3100

Authors: Sarina A. Piha-Paul, Noboru Yamamoto, Yasutoshi Kuboki, Howard Safran, Ifode Ajari, Saki Takahashi, Mayuko Sekiya, Ryo Sawamoto, Hiroko Ueki, Satoe Kawakami

Institutions: The University of Texas MD Anderson Cancer Center, National Cancer Center Hospital, National Cancer Centre Japan, National Cancer Center Hospital East, Rhode Island Hospital, Lifespan, Chugai Pharma (United States), Chugai Pharmaceutical Co., Ltd. (Japan)

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Chugai Pharmaceutical

OpenAlex ID: W4410822866

Cites:

Cited by:

Related to: 10